Disclaimer

This presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. This presentation has not been examined, reviewed or compiled by the Company’s independent certified accountants.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company’s control or with in the Company’s control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations.

Sept 2015
Collagen Solutions plc : Collagen

- Main constituent of mammalian ECM
  - especially type I

- Biodegradability

- Biocompatibility
  - low interspecies rejection
  - low immunogenicity and antigenicity

- Relatively abundant in nature

- Ideal for cell culture

- Versatile
Collagen Solutions plc: Applications

- Improving biocompatibility
  - e.g. by coating devices for implant

- Diagnostic kits
  - e.g. ELISA
  - Tissue models

- Drug delivery
  - ophthalmology (films, inserts, plugs, shields)
  - protein delivery
  - anti-cancer therapy

- Cosmetics
  - dermal fillers
  - face creams
Collagen Solutions plc: TERM Applications

- Collagen is used for the development of a variety of tissue engineering scaffolds
  - provides support for cells
  - allows for regeneration of natural ECM

- Artificial skin
  - cells cultured on or in a collagen scaffold
  - repair or replace damaged/diseased tissue
  - cells encourage deposition of new ECM material

- Wound dressings
  - natural haemostat
  - can be resorbed by the body
  - encourages cell proliferation and hence wound repair
Collagen Solutions plc : TERM Applications

- Bone fillers
  - osteoblasts mixed with collagen to promote deposition of new healthy bone

- Cartilage repair/replacement
  - chondrocytes mixed with collagen to promote deposition of new healthy cartilage

- Decellularised tissues
  - e.g. heart valves, dermis
  - physical, chemical and enzymatic treatments used to remove cells and other material that could elicit an immune response
  - scaffold may then be seeded with the patients own cells
Collagen Solutions plc

www.collagensolutions.com
Collagen Solutions plc : Background

• Collbio Ltd established March 2013

• Collagen Solutions plc established January 2\textsuperscript{nd} 2014

• Collbio Limited Acquisition of Collagen Solutions LLC and reversal into AIM-listed Healthcare Investment Opportunities

• Collagen Solutions plc acquires Southern Lights Biomaterials by way of a reverse takeover

• Locations: UK, USA and NZ
We are experts in the sourcing and provision of *functional* medical grade collagen-based biomaterials for use in medical devices and regenerative medicine – at every stage in the value chain.
Collagen Solutions Global Reach

New Zealand
- Primary Processing
- Sourcing and clean room Manufacturing

USA
- Research and Development
- Formulation and Device Development

UK
- Clean room Manufacturing
- Sterile supply and Device Manufacturing

www.collagensolutions.com
A De-Risked Business Model

- Manufacture
- Multiple customers
- Multiple sectors
- Multiple products
- Research & development
- Supply of platform products
- Research & Diagnostics
- Medical Devices
- Regenerative Medicine

Time to Revenue
FDA Approvals : Customer Case Studies

1. Diabetic Ulcer Treatment (Taxus Cardium)
Development and Manufacture of 510K Medical Device

2. Burns Treatment : Autologous Cell Therapy Scaffold
Utilised customer IP and COS material and know-how to optimise scaffold product - FDA IND approved – COS is the manufacturer.

3. Bone graft : Globus Medical Inc.
Collagen powder supply

Collagen Solutions products are embedded within customers devices by virtue of their functionality and regulatory approval – this means we have “sticky” revenues.

www.collagensolutions.com
Collagen Solutions Quality

• ISO 13485 (CFR 21 Part 820).

• ISO 22442 (PI, II, III).

• EDQM Certificates.
  • Australia
  • New Zealand

• cGMP B and C Clean rooms

• Viral inactivation validation.

• Produced FDA approved device.
Customer, Products, Markets

- DESU medical → Brain Stent → Turkey
- GLOBUS MEDICAL → Bone graft → USA
- NOVABONE → Wound care → USA
- KHERON Medical Innovations → Bone graft → Netherlands
- Customer X → Bone graft → Korea

www.collagensolutions.com
Collagen Team - Board

David Evans, Chairman
David has a proven track record in acquiring, integrating and growing businesses in the diagnostic area and has extensive plc and private company board experience. Former Chairman of BBI Holdings Plc, Horizon Discovery Ltd, Immunodiagnostics Systems Holdings Plc, DxS Limited, Epistem Holdings Plc and Sirigen Group Ltd. David is currently Chairman of EKF Diagnostics Holdings Plc, Scancell Holdings Plc, Omega Diagnostics Group Plc, Venn Life Sciences Holdings Plc, OptiBiotix Health Plc and Premaitha Health Plc.

Stewart White, CEO
Stewart has international experience in operations, business and product development, and ‘Good Manufacturing Practices’ (GMP) compliant manufacturing of collagen medical devices, advanced biologics and Active Pharmaceutical Ingredients in both Small to Medium Enterprises as well as global pharmaceutical companies. Stewart holds a First Class degree in Applied Microbiology, a Ph.D. in Fermentation Technology & Bioprocessing and an MBA.

Gill Black, CFO
Gill brings extensive financial Board-level experience to the Group, having been Financial Director and Company Secretary of A&E Russell Ltd, guiding the company through the acquisition by Bunzl plc in 2008. She was Head of Finance at AKP Scotland Ltd and GVA James Barr Ltd, where she was also Company Secretary, until it was acquired by GVA Grimley, now part of Bilfinger Real Estate. Previously, Gill who is a Chartered Accountant, was Senior Manager at KPMG advising high growth businesses.

Geoff Bennett, CBO
Geoff co-founded Southern Lights Biomaterials in 2003. He has financial and operational experience including previously holding the chief financial role at three publicly traded Canadian companies (Pelorus Navigation Systems Inc., Circle Energy Inc. and Solid State Geophysical Inc.) as well as experience of early stage enterprises specialising in technology commercialisation.

Kevin Wilson, Non-Executive Director
Kevin has spent over 25 years as a securities analyst and corporate finance adviser in both stockbroking and investment banking, providing advice to a wide range of smaller public and private companies. He is a director of AIM listed EKF Diagnostics Holdings Plc and a former director of BBI Holdings Plc.

Malcolm Gillies, Non-Executive Director
Malcolm is a director in several private companies mostly involved in the healthcare area. He has previously held positions as a NED in public companies and was company secretary at Axis-Shield Plc. He has a background as a corporate finance lawyer, having been a senior partner with Shepherd and Wedderburn.
Collagen Team - Senior Management

Jacci Burgin, Chief Scientific Officer
Jacci has worked in the biomedical polymer field since 1987 with significant experience in product development to scale-up and manufacturing. She has been co-inventor on 17 patents, mainly utilising collagen in medical devices. Other areas of research include polyethylene glycols, glycol-amino glycans and hyaluronic acid. She holds a BSc in Chemistry from the University of California.

Diane Mitchell, Chief Commercial Officer
Diane has extensive sales and marketing experience in collagen and medical devices, managing a diverse customer base including blue-chip companies, academic collaborators and start-ups, having established distribution networks for biomaterials and devices. She holds a degree in Business Administration and an MBA from the University of Phoenix.

Dr John Higgins, Chief Technology Officer
John is a biochemical engineer and life science start-up enthusiast, with a focus on R+D and strategy development and execution. John has been integral to the success of Southern Lights (SLB). He has particular expertise in understanding the performance characteristics of proteins and polymers in the manufacturing process and system characterisation. He developed SLB’s Type I collagen process and the pericardium preservation process. John holds a Ph.D in Biotechnology and a B. Tech (Biotech) from Massey University and an M.E. (Chem) from the University of Canterbury.

Tom Hyland, Chief Operating Officer
Tom has a wealth of experience in the field of collagen chemistry, development, manufacturing, validation and engineering requirements of collagen-based medical devices with global life science companies, including Johnson & Johnson Wound Care Management and Alere Technologies. Tom holds an honours degree in Chemistry / Chemical Engineering from Paisley University, an MBA from Heriot Watt University and is a Black Belt in Process Excellence.

Prof Robert Brown, Scientific Adviser
Robert is Director of Research at the Centre for Tissue Regeneration Science within the Institute of Orthopaedics and Musculo-Skeletal Sciences (Division of Surgery) in the UCL Medical School. He is an exclusive consultant and is a member of the Group’s Scientific Advisory Board.
Strategic Opportunities

1. Cross-sell and up-sell into new customers and territories

2. Develop Process and Device related IP
   - Pericardium patent approved in US.
   - Other products

   Burns       Cartilage Repair       Diabetic Foot Ulcers

3. Collaborations
   - The Electrospinning Company Ltd (Innovate UK)
   - UCL/Oxford MEStar (Arthritis Research UK)
   - Parkinson’s Disease (H2020 – NUI Galway Consortium)
   - University of Strathclyde (Medical Research Scotland)

www.collagensolutions.com
Why Collagen Solutions?

- >50 years management experience in Sourcing, Production, Exploitation
- Engaged and diverse customer base (Asia, EU, USA)
- Existing and embedded Revenues and IP
- De-risked and evolving business model
- A turn-key value offering – raw materials to finished device.
- SLB acquisition – additive and complementary.
- Engaged Customer Base because:
  - Control cost
  - Decrease time to market
  - Embed value
Collagen Solutions plc (COS)

Thank you

www.collagensolutions.com